This is a StockGuru Spotlight on Access Pharmaceuticals, Symbol: ACCP

About the Company:

Access Pharmaceuticals, Inc. is an emerging pharmaceutical company focused on the development and commercialization of proprietary products for the treatment and supportive care of cancer patients. Access has one approved product, two products in Phase 2 development, and five preclinical development programs. The company’s approved product is MuGard(TM) for the management of oral mucositis (a common and debilitating side effect of many cancer therapies) for which marketing authorization has been allowed by the FDA. Access’ ProLindac(TM), a polymer-linked platinum cancer drug is in Phase 2 clinical testing in cancer patients, as is Phenylbutyrate, a pleotropic agent which current evidence suggests acts as both an HDAC inhibitor and a differentiating agent. The Company’s preclinical development programs include Angiolix, a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is potentially targeted to a number of tumor types, including breast and ovarian; Prodrax, a non-toxic prodrug which is activated in the hypoxic zones of solid tumors to kill tumor cells; Alchemix, a chemotherapeutic agent that combines two modes of action to overcome drug resistance, and oral insulin, which utilizes the company’s Cobalamin(TM) oral drug delivery technology.Dallas,TX,.

Phone number for the company: (214) 905-5100.

Executive Contact: Christine Berni,IR.